Four domains and twelve entry points: the WHO blueprint on fungal disease

Guidance, not a new pathogen list

The World Health Organization published the Blueprint for strengthening responses to fungal disease and antifungal resistance on 30 June 2026, under the subtitle Implementation guidance. The page carrying it is labelled a departmental update rather than a news release from the organisation as a whole, and the distinction is worth preserving, because the document commits nobody to anything. The departmental update says WHO has published a blueprint to help countries respond to a rising burden, and calls fungal disease and antifungal resistance one of global health's most underestimated and neglected threats.

The guidance builds on the fungal priority pathogens list of 25 October 2022 and on existing WHO work covering neglected tropical diseases, HIV and antimicrobial resistance. It does not revise that list: nothing is added, nothing is re-ranked, no new ranking is announced. The publication record says the guidance responds to requests from Member States, regional bodies and global partners for something practical enough to operationalise.

The burden gets a single sentence: fungal diseases affect more than 300 million people each year and are associated with high mortality, long-term illnesses and major losses in health and productivity worldwide. That figure counts people affected, not deaths, and no mortality number appears anywhere on the page; the report's own executive summary refers to millions of deaths a year without putting a figure to that either. Despite the toll, the update continues, fungal diseases remain largely absent from national health plans, from global burden-of-disease estimates, and from most antimicrobial resistance, universal health coverage and One Health strategies. The growth in resistance is blamed, in a framing sentence of its own rather than in the description of any domain, on the widespread use of antifungals and their analogues across human, animal and plant health, and on environmental exposure to antifungal chemicals.

The domains, the entry points and how they were chosen

Action is organised under four interlinked domains: public health and health system interventions (awareness, system readiness, antifungal stewardship programmes, workforce training, infection prevention and control); the advancement of therapies, tools and innovation (equitable access to quality-assured medicines and diagnostics, research and market incentives through coordinated regulatory and financing mechanisms); laboratory systems, surveillance and outbreak preparedness (resilient laboratory networks, integrated surveillance, better diagnostics and data quality); and social and environmental drivers, meaning the agricultural, environmental and social determinants of fungal disease and resistance, approached through cross-sectoral One Health work. Alongside them sit an implementation logic framework and twelve catalytic entry points, meant to guide national and regional prioritisation of interventions and investments so as to achieve measurable outcomes. The stated aim is to close gaps in knowledge, diagnosis, treatment, surveillance, research and workforce capacity, with particular attention to low-resource settings.

The methodological annex to the full text shows how that list was assembled. Twenty-five experts first tested the four-domain framework at a workshop during the 2024 ESCMID congress in Barcelona. Eight virtual roundtables then drew more than 150 participants, from clinical mycology and diagnostics through surveillance, regulatory policy and procurement to patient advocacy, and generated over 130 proposed actions. Each was scored for public health impact, operational feasibility and scalability, and the results went to a two-day technical consultation in October 2024 where more than 50 people settled priorities in breakout groups and structured digital polling.

Two people are quoted, and only two. Dr Jean Pierre Nyemazi, Director a.i. of the Department of Antimicrobial Resistance at WHO, says the updated Global Action Plan on antimicrobial resistance approved by the Seventy-ninth World Health Assembly recognised antifungal resistance as an integral part of the resistance challenge, one that can no longer be overlooked, and that the Blueprint gives countries a concrete path forward. Hatim Sati, a technical officer in the same department who led the document's development, says fungal disease and antifungal resistance remain an under-addressed priority across national health plans, resistance strategies and surveillance systems.

What the blueprint does not settle

This is not a clinical guideline, a regulation or a treaty obligation. The announcement attaches no dates, no budgets and no numbered indicators to the twelve entry points; it speaks of measurable outcomes without saying what would be measured or by whom. The report itself adds an annex of three implementation phases, while stating that these reflect relative implementation complexity rather than fixed timelines and that the phasing is illustrative and non-prescriptive. Read as a commitment, the document disappoints; read as a shared vocabulary a health ministry can lift into a plan of its own, it is attempting something more modest and rather more plausible.

Two traps are worth marking. The news item words two of the four domains differently from both the publication record and the report itself: it writes of the advancement of therapies, tools and innovation and of social and environmental drivers where the report writes of therapies, technologies and innovation systems and of social, environmental and One Health drivers. That is one document in two sets of words, not two versions of a plan. And if an annual death toll for fungal disease turns up beside this announcement, it comes from some other piece of work, because WHO gives no such number here.

What can be checked from here

The document carries ISBN 978-92-4-012252-9 and is released under CC BY-NC-SA 3.0 IGO. That licence sits outside the set we are able to reproduce from, which is why this article links to the Blueprint rather than lifting a single figure out of it. A launch event was listed for 1 July 2026, from 14.00 to 15.30 CET; the WHO page links neither a recording nor a report, so nothing about the session itself can be established from it.

WHO's update of 25 May 2026 repays a look as well. It describes the revised global action plan that member states adopted on 23 May, and it does not contain the word fungal or antifungal anywhere, speaking instead of antimicrobials in general. That does not contradict Nyemazi, since the recognition he describes would live in the plan's own text rather than in a note about its adoption. It does illustrate how readily fungi drop out of the resistance conversation, which is the habit this Blueprint is trying to break.

The most useful test of a document like this is local and needs no database at all. Open your own country's national action plan on antimicrobial resistance and count how often the words fungus or fungal appear in it. The Blueprint exists in part because, as WHO puts it, fungal disease is absent from most such strategies.